1. Identify the neuromuscular blocking agent that is associated with malignant hyperthermia.
2. Identify the negative outcome that can result from relying only on clinical features that do not include sputum culture to diagnose VAP.
3. List causes and risk factors for VAP.
4. Describe the pathogenesis of VAP.
5. List clinical findings seen with VAP.
6. Identify the most common organism type seen in VAP.
7. Identify the incidence of VAP for all intubated patients.
8. Identify the common bacteria seen in the upper airway of healthy people.
9. Identify the clinical lab study that contributes the most toward the effective treatment of VAP.
10. List commonly used benzodiazepines in the ICU.
11. Identify time required for the onset of symptoms for a respiratory infection to be considered VAP.
12. Identify the most useful feature of dexmedetomidine (Etomidate) in the ICU.
13. List items typically included in a ventilator bundle.
14. Identify the mortality rate for VAP.
15. List items included in the updated definition of VAP.
16. List interventions that may reduce the risk of VAP.
17. Differentiate features of mild, moderate and deep sedation.
18. Identify the medication type that may be useful in a case where patient-ventilator asynchrony cannot be corrected.
